Press Releases

2011

June 2011 - Aqix Ltd wins a competition award of £60k as part of the Technology Strategy Board Grant for Research and Development to fund the pilot investigation of AQIX® RS-I in the only UK survival model of cardiopulmonary bypass in collaboration with the University of Bristol.

2010

July 2010 - Aqix Ltd wins a competition award of £330k as part of the Technology Strategy Board Regenerative Medicine Programme for Developing Therapeutics to fund the further development of AQIX® RS-I and extended research into organ transplant application in collaboration with the University of Newcastle.

2009

November 2009 - Aqix Ltd wins a competition award of £100k as part of the Technology Strategy Board Regenerative Medicine feasibility studies to fund the development of AQIX® RS-I.

2008

February 2008 - DrugMode, Denmark. AQIX® RS-I adopted as pre-incubation medium in data base for isolation of human hepatocytes used in drug throughput bioassay procedures.

March 2008 - Cureline Inc., USA/USSR. Aqix Ltd enters a co-marketing agreement with Cureline Inc. a custom tissue acquisition provider with an emphasis on custom human tissue acquisition for target validation, drug discovery, diagnostic and clinical development.

September 2008 - Res-Del® Ltd, New Zealand. AQIX® RS-I adopted as perfusate solution in the data base for perfusion of animal and human biopsies using the patented horizontal Res-Del® 591 Organ Perfusion/Perifusion Bath System.

2007

December 2007- Biopta, UK. AQIX® RS-I adopted as data base for storage, transportation and normothermic perfusion of human cadaver tissue biopsies used in drug bioassay procedures

2006

March 2006 – Bowman Research/Organ Recovery Systems, Belgium/USA. AQIX® RS-I adopted as data base for Ex Vivo perfusion of KPS-1 human cadaver organs used in drug bioassay procedures.